Piramal Pharma Ltd
Piramal Pharma Ltd Company History
Piramal Pharma offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated Contract Development and Manufacturing Organisation (CDMO), Piramal Critical Care (PCC), a Complex Hospital Generics business, and the India Consumer Healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies. PCC’s complex hospital product portfolio includes inhalation anaesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anaesthetics, injectable anti-infectives, and other therapies. The India Consumer Healthcare business is among the leading players in India in the self-care space, with established brands in the India consumer healthcare market. In addition, PPL has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. In October 2020, the company received a growth equity investment from the Carlyle Group.
2020
Acquired pharmaceutical business from PEL
20% Strategic Growth Investment by Carlyle
Increased stake to 100% in CCPL
Piramal Pharma and Navin Fluorine Mutually Agree on Piramal Increasing its Stake to 100% in Convergence Chemicals.
Piramal Pharma Solutions to Collaborate with Epirium Bio on Exclusive Integrated Development & Manufacturing Program for Orphan Drugs.
Piramal Pharma Solutions Announces Integrated Development Program with Bolt Biotherapeutics for Immune-Stimulating Antibody Conjugates and Sterile Fill-Finish
Piramal Critical Care Announces Strategic Partnership with US-Based Pharmaceutical Outsourcing Facility Medivant Healthcare
2020
2021
Acquisition of HPPL
Piramal Pharma Solutions Announces Winner of its Inaugural Award for Excellence in Patient Centricity.
Piramal Pharma Solutions Enters Into a Master Services Agreement with Plus Therapeutics, Inc.
Piramal Pharma LimitedÂs Consumer Products Division Launches Âi-feel®Â
2021
2022
Acquisition of minority stake in Yapan Bio Private Limited
Composite Scheme of Arrangement under the provisions of section 230 to 232 and other applicable provisions of the Companies Act, 2013 amongst PEL, the Company, CCPL, HPPL, PFPL and their respective shareholders and creditors, sanctioned by the NCLT on August 12, 2022. Pursuant to the Scheme, Demerged Undertaking of PEL, transferred and vested into the Company.
Piramal Pharma Solutions Announces Winner of its September 2022 Award for Excellence in Patient Centricity.
Piramal Pharma Solutions Launches ADCelerate, a Rapid, Integrated Approach to Taking ADCs to IND.
Piramal Pharma Solutions Holds Grand Opening Ceremony for New API Plant at Aurora, Canada Manufacturing Site.
Piramal Pharma Solutions New API Plant in Canada Goes Online; Initial Production Runs Successfully Completed.
2022
2023
Company issued rights shares of Rs. 10 in the ratio of 5:46 at a premium of Rs. 71 per share.
2023
